Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status.
Year: 2017
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Katja C. Weisel, Jesus San Miguel, Gordon Cook, Merav Leiba, Kenshi Suzuki, Shaji Kumar, Michele Cavo, Herve Avet-Loiseau, Hang Quach, Vania Hungria, Suzanne Lentzsch, Roman Hajek, Pieter Sonneveld, Kaida Wu, Xiang Qin, Christopher Chiu, David Soong, Ming Qi, Jordan Mark Schecter, Meletios A. Dimopoulos
Institutions: Universitätsklinikum Tübingen, University of Tübingen, Clinica Universidad de Navarra, University of Leeds, Leeds Teaching Hospitals NHS Trust, Sheba Medical Center, Japanese Red Cross Medical Center, Mayo Clinic, University of Bologna, Hôpital Rangueil, The University of Melbourne, St Vincent's Hospital Melbourne, Irmandade da Santa Casa de Misericórdia de São Paulo, Columbia University, University of Ostrava, University Hospital Ostrava, Erasmus MC, Janssen Research & Development (United States), National and Kapodistrian University of Athens
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2761237722